JP2021518129A5 - - Google Patents

Info

Publication number
JP2021518129A5
JP2021518129A5 JP2020550598A JP2020550598A JP2021518129A5 JP 2021518129 A5 JP2021518129 A5 JP 2021518129A5 JP 2020550598 A JP2020550598 A JP 2020550598A JP 2020550598 A JP2020550598 A JP 2020550598A JP 2021518129 A5 JP2021518129 A5 JP 2021518129A5
Authority
JP
Japan
Prior art keywords
flagellin polypeptide
polypeptide
composition
flagellin
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020550598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518129A (ja
Filing date
Publication date
Priority claimed from GBGB1804384.4A external-priority patent/GB201804384D0/en
Priority claimed from GBGB1809953.1A external-priority patent/GB201809953D0/en
Priority claimed from GBGB1811900.8A external-priority patent/GB201811900D0/en
Priority claimed from GBGB1812378.6A external-priority patent/GB201812378D0/en
Priority claimed from GBGB1813444.5A external-priority patent/GB201813444D0/en
Priority claimed from GBGB1813423.9A external-priority patent/GB201813423D0/en
Priority claimed from GBGB1816834.4A external-priority patent/GB201816834D0/en
Priority claimed from GBGB1817641.2A external-priority patent/GB201817641D0/en
Priority claimed from GBGB1901218.6A external-priority patent/GB201901218D0/en
Priority claimed from GBGB1901199.8A external-priority patent/GB201901199D0/en
Priority claimed from GBGB1901992.6A external-priority patent/GB201901992D0/en
Priority claimed from GBGB1901993.4A external-priority patent/GB201901993D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/056809 external-priority patent/WO2019180000A1/en
Publication of JP2021518129A publication Critical patent/JP2021518129A/ja
Publication of JP2021518129A5 publication Critical patent/JP2021518129A5/ja
Priority to JP2023072015A priority Critical patent/JP2023100747A/ja
Pending legal-status Critical Current

Links

JP2020550598A 2018-03-19 2019-03-19 組成物 Pending JP2021518129A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023072015A JP2023100747A (ja) 2018-03-19 2023-04-26 組成物

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
GB1804384.4 2018-03-19
GBGB1804384.4A GB201804384D0 (en) 2018-03-19 2018-03-19 Compositions
GB1809953.1 2018-06-18
GBGB1809953.1A GB201809953D0 (en) 2018-06-18 2018-06-18 Compositions
EP18178350.7 2018-06-18
EP18178350 2018-06-18
GBGB1811900.8A GB201811900D0 (en) 2018-07-20 2018-07-20 Compositions comprising bacterial strains
GB1811900.8 2018-07-20
GB1812378.6 2018-07-30
GBGB1812378.6A GB201812378D0 (en) 2018-07-30 2018-07-30 Compositions comprising bacterial strains
GBGB1813444.5A GB201813444D0 (en) 2018-08-17 2018-08-17 Compositions
GB1813444.5 2018-08-17
GBGB1813423.9A GB201813423D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GB1813423.9 2018-08-17
GBGB1816834.4A GB201816834D0 (en) 2018-10-16 2018-10-16 Compositions
GB1816834.4 2018-10-16
GB1817641.2 2018-10-29
GBGB1817641.2A GB201817641D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GB1901218.6 2019-01-29
GBGB1901199.8A GB201901199D0 (en) 2019-01-29 2019-01-29 Compositions comprising bacterial strains
GBGB1901218.6A GB201901218D0 (en) 2019-01-29 2019-01-29 Compositions
GB1901199.8 2019-01-29
GB1901993.4 2019-02-13
GBGB1901992.6A GB201901992D0 (en) 2019-02-13 2019-02-13 Compositions comprising bacterial strains
GB1901992.6 2019-02-13
GBGB1901993.4A GB201901993D0 (en) 2019-02-13 2019-02-13 Compositions
PCT/EP2019/056809 WO2019180000A1 (en) 2018-03-19 2019-03-19 Compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023072015A Division JP2023100747A (ja) 2018-03-19 2023-04-26 組成物

Publications (2)

Publication Number Publication Date
JP2021518129A JP2021518129A (ja) 2021-08-02
JP2021518129A5 true JP2021518129A5 (https=) 2022-03-09

Family

ID=65955185

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020550823A Pending JP2021518414A (ja) 2018-03-19 2019-03-19 細菌株を含む組成物
JP2020550598A Pending JP2021518129A (ja) 2018-03-19 2019-03-19 組成物
JP2023072015A Pending JP2023100747A (ja) 2018-03-19 2023-04-26 組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020550823A Pending JP2021518414A (ja) 2018-03-19 2019-03-19 細菌株を含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023072015A Pending JP2023100747A (ja) 2018-03-19 2023-04-26 組成物

Country Status (25)

Country Link
US (3) US11419931B2 (https=)
EP (3) EP3768284B1 (https=)
JP (3) JP2021518414A (https=)
KR (2) KR20210003096A (https=)
CN (2) CN112004543A (https=)
AU (2) AU2019238358A1 (https=)
BR (2) BR112020019008A2 (https=)
CA (2) CA3094297A1 (https=)
CY (1) CY1125104T1 (https=)
DK (1) DK3768284T3 (https=)
ES (1) ES2908826T3 (https=)
HR (1) HRP20220368T1 (https=)
HU (1) HUE058151T2 (https=)
IL (2) IL277422A (https=)
LT (1) LT3768284T (https=)
MA (1) MA52128A (https=)
MD (1) MD3768284T2 (https=)
MX (2) MX2020009736A (https=)
PL (1) PL3768284T3 (https=)
RS (1) RS63090B1 (https=)
SG (2) SG11202009254YA (https=)
SI (1) SI3768284T1 (https=)
SM (1) SMT202200111T1 (https=)
TW (2) TW202003001A (https=)
WO (2) WO2019180051A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
US20230022045A1 (en) * 2019-12-03 2023-01-26 Board Of Regents, The University Of Texas System Combination therapies for the treatment of cancer
EP4161541A4 (en) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS
US12350300B2 (en) 2021-10-08 2025-07-08 Iowa State University Research Foundation, Inc. Use of dopamine producing products to increase vaccine efficacy
CN113999923B (zh) * 2021-11-25 2024-05-14 上海金翌生物科技有限公司 小柳-原田综合症标志微生物及其应用
CN115287243B (zh) * 2022-04-15 2023-06-06 集美大学 一株变形假单胞菌flgK基因沉默菌株及其构建方法
JPWO2024096122A1 (https=) * 2022-11-04 2024-05-10
KR102878250B1 (ko) 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20080025977A1 (en) 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
CN101595133B (zh) 2006-10-27 2012-11-14 比利时胶囊公司 羟丙基甲基纤维素硬胶囊及制备方法
EP1958647A1 (en) 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
DK2133092T3 (en) * 2007-03-19 2016-01-11 Morishita Jintan Co Oral vaccine
BRPI0911604A2 (pt) * 2008-04-25 2015-12-15 Inst Systems Biology vacinas de polipeptídeo de flagelina
CA2777198C (en) * 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
WO2012097012A1 (en) 2011-01-10 2012-07-19 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
US10786637B2 (en) 2011-07-13 2020-09-29 Pharmaxis Ltd. Delivery devices
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
FR2989002B1 (fr) 2012-04-10 2015-05-15 Beepratte Lab Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique
CA2884816A1 (en) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3104885A4 (en) * 2014-02-12 2017-08-30 Transalgae (Israel) Ltd Algal based edible vaccines
GB201520502D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3630942B1 (en) * 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
MX392976B (es) 2017-08-10 2025-03-24 4D Pharma Res Limited Composiciones que comprenden cepas bacterianas.
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains

Similar Documents

Publication Publication Date Title
JP2021518129A5 (https=)
US7635479B2 (en) Composition and methods for enhancing immunogenecity of antigens
US6767542B2 (en) Compositions and methods for enhancing immunogenicity of antigens
HRP20220368T1 (hr) Pripravci entereococcus flagellin za uporabu u liječenju
JP2023513720A5 (https=)
US20080124354A1 (en) Methods for administering tumor vaccines
RU2016145464A (ru) Рекомбинантные вакцинные штаммы listeria и способы их получения
CA3125184A1 (en) Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
JP2011500718A5 (https=)
JP2022130623A5 (https=)
CN111154806A (zh) 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
JP2018536002A5 (https=)
RU2021109510A (ru) Вакцинация с использованием альфа 3 домена mica/b для лечения рака
JP2019013229A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
JP2014139185A5 (https=)
FI3737397T3 (fi) Prameen kohdistetut syöpärokotteet ja niiden käytöt
CN111295200B (zh) 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
Lu et al. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope
US20220152168A1 (en) Sequential heterologous boost oncolytic viral immunotherapy
PH12020500194A1 (en) Malaria vaccine
JP2006501166A5 (https=)
JP2022512686A5 (https=)
JP7454320B2 (ja) アジュバントとしての腫瘍溶解性ウイルス
KR20250065615A (ko) 헬리코박터 파일로리 감염에 대한 백신
WO2024075067A1 (en) Cancer vaccine composition that comprises a host cell expressing glypican-1 (gpc-1)